Concepedia

Peter Ordentlich

PO

Statistics

Publications

48

Citations

6.5K

H-Index

34

Active since

1991

Affiliations

Synta Pharmaceuticals (United States)(Current)

Roswell Park Comprehensive Cancer Center

The Wistar Institute

Dana-Farber Cancer Institute

Howard Hughes Medical Institute

Peter Ordentlich is an author at Synta Pharmaceuticals (United States) specializing in medicine, oncology, and pharmacology.

ORCID

Publications per year

1991–2024

48

Publications

48

Cancer-Associated Fibroblasts Neutralize the Anti-tumor Effect of CSF1 Receptor Blockade by Inducing PMN-MDSC Infiltration of Tumors

Vinit Kumar, Laxminarasimha Donthireddy, Douglas Marvel et al. · Cancer Cell · 2017 · 647 citations · Full text

, , +17

A histone deacetylase corepressor complex regulates the Notch signal transduction pathway

Hung‐Ying Kao, Peter Ordentlich, Naoko Koyano‐Nakagawa et al. · Genes & Development · 1998 · 576 citations · Full text

, , +17

A Natural Product That Lowers Cholesterol As an Antagonist Ligand for FXR

Nancy L. Urizar, Amy B. Liverman, D'Nette T. Dodds et al. · Science · 2002 · 543 citations

, , +17

The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia

Ghayas C. Issa, Ibrahim Aldoss, John F. DiPersio et al. · Nature · 2023 · 468 citations · Full text

, , +13

Isolation of a novel histone deacetylase reveals that class I and class II deacetylases promote SMRT-mediated repression

Hung‐Ying Kao, Michael Downes, Peter Ordentlich et al. · Genes & Development · 2000 · 424 citations · Full text

, , +13

1–5 of 48